Characterizing type 2 diabetes (T2D) subtypes in the U.S. to improve prevention, diagnosis, treatment, and management
Definition, Etiology, Function: INtegration to Enhance Type 2 Diabetes treatment (DEFINE-T2D) Consortium
In 2024, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) funded the DEFINE-T2D consortium to better understand heterogeneity in T2D. Leveraging data on clinical, genetics, omics, environmental exposures, lifestyle behaviors, and social factors, major goals of DEFINE-T2D are to: 1) develop a broadly applicable framework for identifying subtypes of T2D; and 2) increase understanding of the physiologic drivers of T2D subtypes to guide development of more effective precision interventions
Get to know who is behind the science! The Investigator and Staff Spotlight series celebrates the stories, interests, and expertise of the DEFINE-T2D community by showcasing the people behind impactful discovery and innovation in diabetes research.
DEFINE-T2D In-Person Meeting
On June 3–4, 2026, DEFINE-T2D investigators gathered in New Orleans ahead of the annual American Diabetes Association meeting. The group engaged in productive discussions focused on strategic milestones, collaborative opportunities, and goals for the remaining three years of the grant cycle, while also sharing updates on the progress of ongoing scientific projects. The meeting provided a valuable opportunity for investigators across the consortium to connect in person, strengthen collaborations, and learn more about the personal and professional interests of several promising early-career investigators. We are grateful for the enthusiasm, insights, and teamwork that continue to drive the DEFINE-T2D program forward. We look forward to reconvening at our next in-person meeting in November 2026 in Denver, Colorado. Stay tuned for meeting dates.
 |  |
CMS Login